Oxford-AstraZeneca Vaccine Set To Become First To Get Approv
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
India's drug regulator is set to approve Oxford-AstraZeneca vaccine, for emergency use. The expert committee set up by Drugs Controller General of India (DCGI) V.G. Somani to vet vaccine proposals, recommended emergency approval for Oxford-AstraZeneca COVID-19 vaccine.

Dubbed as Covishield in India, the Oxford-AstraZeneca COVID-19 vaccine showed an average efficacy of 70.4%, with no hospitalisations or severe disease, the researchers claimed. Serum Institute sought emergency use licence for a version of the British drugmaker’s vaccine in India last month.

The vaccine is virus-vectored, which means it is a version of a virus that normally infects chimpanzees and has been modified with a portion of the COVID-19 called the spike protein to fire the immune system. Once in human cells, the vaccine should help stimulate the production of antibodies that recognize the virus.

Cheaper and easier to distribute than rival vaccines, the Oxford-AstraZeneca COVID-19 vaccine is by far the most significant in the global fight against the novel coronavirus. Researchers claim the vaccine protected against disease in 62% of those given two full doses and in 90% of those initially given a half dose.

India will be the first priority for the delivery of the AstraZeneca-Oxford vaccine, Adar Poonawalla, chief executive officer, Serum Institute of India, earlier mentioned. "The COVID-19 vaccine will be distributed initially in India, then we will look at the COVAX countries which are mainly in Africa. Our priority is India & COVAX countries," Poonawalla said.

Dr. T●●●●z H●●●●●●i and 6 others like this6 shares